Clinical Trials Logo

Urologic Neoplasms clinical trials

View clinical trials related to Urologic Neoplasms.

Filter by:

NCT ID: NCT06443944 Available - Bladder Cancer Clinical Trials

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Start date: n/a
Phase:
Study type: Expanded Access

This is an open-label, expanded access trial designed to provide access to cretostimogene in patients with NMIBC unresponsive to BCG.

NCT ID: NCT06427057 Not yet recruiting - Clinical trials for Urinary System Tumor

A Study of Cadonilimab(AK104)Combined With Standard Treatment for Function Preservation in Urinary System Tumors

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

This is an open label, dual cohort ,phase II study to explore efficacy and safety of cadonilimab(PD-1/CTLA-4 Bispecific Antibody) combined with standard regimen neoadjuvant treatment in urothelial carcinoma(UC) and renal cell carcinoma(RCC), with evaluating successful preservation rate of bladder/kidney.

NCT ID: NCT06398314 Not yet recruiting - Gynecologic Cancer Clinical Trials

Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors

PALLSOFT
Start date: September 2024
Phase: N/A
Study type: Interventional

PALLSOFT is a randomized, open-label, non-inferiority phase III, multicenter, national trial that will investigate whether the patient-reported symptomatic effect of palliative radiotherapy delivered in 1-2 fractions is non-inferior to palliative radiotherapy delivered in five fractions in patients with pelvic soft tissue tumors from either gastrointestinal, urological or gynecological cancer. Health-related quality of life, toxicities, survival and prognostic and predictive biomarkers will be assessed as secondary and explorative endpoints.

NCT ID: NCT06397287 Recruiting - Surgery Clinical Trials

PROM Project Urology

Start date: September 5, 2023
Phase:
Study type: Observational

All patients undergoing urological surgery or treatment should receive standardized questionnaires on quality of life, satisfaction, pain and physical recovery. Indication-specific, individual pathways are set up, for example, for patients with localized prostate cancer, benign prostate enlargement, bladder dysfunction or erectile dysfunction. In combination with the clinical data, the PROM data should help to improve the quality of the results and, if necessary, adapt treatment pathways to patient needs.

NCT ID: NCT06357416 Recruiting - Hypertension Clinical Trials

The Man Van Project

MV
Start date: April 13, 2022
Phase: N/A
Study type: Interventional
Read more »
NCT ID: NCT06353906 Not yet recruiting - Urologic Neoplasms Clinical Trials

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

PRIAM
Start date: June 14, 2024
Phase: Phase 2
Study type: Interventional

This is a single-armed, single-centre, non-blinded phase II trial to assess efficacy of induction chemo-immunotherapy for resectable node-positive squamous cell carcinoma of the penis

NCT ID: NCT06282354 Not yet recruiting - Surgery Clinical Trials

Telemedicine for Postoperative Follow-up After Oncological Surgeries

Start date: March 1, 2024
Phase:
Study type: Observational [Patient Registry]

The study will be a prospective, randomized, non-inferiority, open-label study, to be carried out at the Cancer Institute of the State of São Paulo for 6 months and will include patients agreeing to voluntary participation upon signing an informed consent form.

NCT ID: NCT06237920 Recruiting - Neoplasms Clinical Trials

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

TURANDORELA
Start date: February 19, 2024
Phase: Phase 2
Study type: Interventional

This is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder preservation after dual immunotherapy would be a viable treatment option for patients responding to treatment

NCT ID: NCT06228066 Recruiting - Clinical trials for Small Cell Carcinoma of the Bladder

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Start date: June 13, 2024
Phase: Phase 2
Study type: Interventional
Read more »
NCT ID: NCT06193941 Completed - Bladder Cancer Clinical Trials

Research on the Accurate Diagnosis of Urinary Tract Tumors and the Development of Kits

Start date: June 1, 2023
Phase:
Study type: Observational

Bladder cancer is the second most prevalent urological malignancy worldwide, with a high incidence and poor patient prognosis. Achieving early diagnosis and intervention for bladder cancer is one of the most important ways to improve clinical management and patient prognosis. Tumor exosomes can be released into biological fluids at an early stage of a tumor, and many studies have shown that exosomal RNA can be used as a reliable biomarker to diagnose tumors in a non-invasive way. Based on the clinical needs for early diagnosis of bladder cancer, we aim to screen several early diagnostic markers with potential predictive value, establish an early diagnostic model for bladder cancer, and validate the validity and reliability of this diagnostic model through a large-scale clinical cohort to complement the diagnosis of early-stage cancers and to improve the rate of early diagnosis of cancer.